Reports & resources developed through the Value & Access Initiative:
What Do Value & Access Really Mean? A Landscape Report on Stakeholder Perspectives – reports on differences in how the “6 Ps”—patients, providers, payers, purchasers, public health, and pharma/biotech—view these issues. It also finds an area of common ground that may enable stakeholders to work together to solve ever-rising healthcare costs and clashes over cost-containment measures. The report documents changes in stakeholders’ views over the last 3 years and a shift from opposition to collaboration on certain issues related to healthcare access and affordability.
Updated SHARED Decision-Making Guides for Providers and Patients to help health care providers engage in shared decision-making conversations with patients about treating and preventing cardiovascular disease. The updated guides include sample questions and talking points providers can use to discuss treatment planning with patients, a fillable treatment planning form, and a patient education handout. Created in collaboration with the Family Heart Foundation, National Lipid Association, and American Pharmacists Association Foundation.
Best Practices for Pharmacy & Therapeutics (P&T) Committees
A checklist modeling processes for P&T Committees to consider when managing the formulary system in making equitable coverage decisions, focusing on evidence-based processes to select and promote treatments offering the best therapeutic outcomes, while minimizing potential risks and costs to patients.
Value & Access: Innovative Collaborations to Improve Access to Evidence-Based Cardiovascular Care
The Value & Access initiative brings together diverse decision-makers from varied stakeholder groups (patients, providers, payers, purchasers, public health and pharma/biotech) to engage in discussion and solution-oriented activities on value and access issues related to cardiovascular health. This white paper outlines accomplishments to date, and the evolution of the initiative.
What Do Value and Access Really Mean? (2016)
Reveals how patients, providers, payers, public health, and industry view the value of therapies and what access means to them.
Members of the Value & Access partnership share information on events and initiatives.
Value Frameworks developed by other organizations – useful resources in the discussion of value and access.
A summary of feedback from members of the Steering Committee and other partners engaged in the value & access space whose reflections represent the spectrum of stakeholder groups.
The Partnership to Advance Cardio Health made the following statement regarding the Institute for Clinical and Economic Review’s (ICER) updated analysis on the value of PCSK9 inhibitors, a breakthrough treatment for patients with high cholesterol.
The Institute for Clinical and Economic Review (ICER) has responded positively to National Forum recommendations to obtain input and include data from several National Forum members for ICER’s upcoming New Evidence Update to its 2015 review on the effectiveness and value of PCSK9 inhibitors. The recommendations stem from the National Forum’s Value & Access Initiative, which has assembled patient, provider, public health, payer and pharma/biotech groups to achieve a consensus goal: Enhance health and well-being by supporting people’s access to evidence-based care that is appropriate for them.
April 3, 2017 letter from the Partnership to Improve Patient Care (PIPC), with support from other patient advocate organizations, providing feedback on the proposed revisions to the Institute for Clinical and Economic Review’s (ICER) value framework.
Traditionally, resource utilization and value considerations have been explicitly excluded from practice guidelines and performance measures formulations, although they often are implicitly considered. This document challenges this historical policy. With accelerating healthcare costs and the desire to achieve the best value (health benefit for every dollar spent), there is growing recognition of the need for more explicit and transparent assessment of the value of health care.